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Purpose: COPD exacerbations are associated with worsening clinical outcomes and 
increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic 
therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary inner-
vation of the lung, has been developed to reduce clinical consequences of cholinergic 
hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the 
durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham 
bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, sympto-
matic COPD two years post randomization.
Patients and Methods: TLD was performed in COPD patients (FEV1 30–60% predicted, 
CAT≥10 or mMRC≥2) in a 1:1 randomized, sham-controlled, double-blinded multicenter 
study (AIRFLOW-2) using a novel lung denervation system (Nuvaira, Inc., USA). Subjects 
remained blinded until their 12.5-month follow-up visit when control subjects were offered 
the opportunity to undergo TLD. A time-to-first-event analysis on moderate and severe and 
severe exacerbations of COPD was performed.
Results: Eighty-two subjects (FEV1 41.6±7.4% predicted, 50.0% male, age 63.7±6.8 yrs, 
24% with prior year respiratory hospitalization) were randomized. Time-to-first severe 
COPD exacerbation was significantly lengthened in the TLD arm (p=0.04, HR=0.38) at 2 
years post-TLD therapy and trended towards similar attenuation for moderate and severe 
COPD exacerbations (p=0.18, HR=0.71). No significant changes in lung function or SGRQ- 
C were found 2 years post randomization between groups.
Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower 
risk of severe AECOPD over 2 years. Further, lung function and quality of life remained 
stable following TLD.
Clinical Trial Registration: NCT02058459.
Keywords: COPD exacerbation, targeted lung denervation, bronchoscopy, COPD
Background
The burden of COPD is well documented with exacerbations associated with 
worsening clinical outcomes1–3 and increased healthcare costs.4,5 In fact, COPD 
is associated with an elevated mortality risk as high as 14-fold the year following 
a severe exacerbation.6 Despite the known risks and growing healthcare burden,7 
therapeutic options which impact exacerbation rate for COPD patients are limited. 
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In fact, it has been reported that 70% of GOLD D patients 
continue to exacerbate despite optimal pharmaceutical care 
(triple therapy, LABA-LAMA-ICS).8 Current inhaled ther-
apeutic options, such as ICS, target symptom relief during 
periods of disease stability and reduction of exacerbation 
risk; however, limitations due to patient compliance, deliv-
ery mechanism, and dose response,9,10 or known associa-
tions with increased rate of pneumonia11,12 result in 
a population of patients with high rates of exacerbations 
despite optimal inhaled pharmaceutical care.8
Acute exacerbations of COPD are predominately dri-
ven by viral and bacterial respiratory infections, which 
have been shown to cause increased reflex signaling via 
the pulmonary branches of the vagus nerve.13,14 The resul-
tant parasympathetic overstimulation drives the release of 
acetylcholine15 and in COPD patients is associated with 
changes in airway inflammation, mucus hypersecretion, 
and airway hyperresponsiveness.2,16,17 Indeed, acute 
increases in symptoms in response to respiratory infection 
(viral or bacterial) are in part secondary to changes in the 
function of the nervous system.18,19 Accordingly, pharma-
cologic blockade of the parasympathetic airway system is 
a known therapeutic target for both acute and chronic 
management of COPD using long-acting muscarinic 
antagonists.20
A novel bronchoscopic therapy, targeted lung denerva-
tion (TLD), ablates the bronchial branches of the vagus 
nerve with the aim to permanently decrease parasympathetic 
stimulation, resulting in decreased airway hyperresponsive-
ness and reduced inflammation, as evidenced through atte-
nuated inflammatory markers.21 Further, preclinical studies 
have demonstrated that the TLD ablation is durable,22 and 
prior clinical results have indicated it is additive to optimal 
medical therapy treatment.23,24 The positive safety profile of 
TLD,23,25,26 as well as clinical impact on severe COPD 
exacerbation rate following targeted lung denervation 
(TLD) has been previously reported.27 Here we present two- 
year follow-up data for the randomized sham-controlled 
AIRFLOW-2 clinical trial.22
Patients and Methods
Study Design and Oversight
This study is the follow-up of a randomized, sham- 
controlled, double-blind, prospective, multicenter study 
designed to evaluate the safety of TLD in patients with 
moderate to severe COPD (AIRFLOW-2 trial – 
NCT02058459). The study design, procedures, and full 
methodology of the AIRFLOW-2 trial has been 
described.27 Following 12.5 months of blinding, sham par-
ticipants were unblinded and offered the opportunity to 
undergo TLD therapy. No preset window of crossover elig-
ibility was defined. Results from subjects who crossed-over 
are limited to those results collected prior to the cross-over 
procedure. All subjects are followed for up to 3 years.
All adverse events were defined by the study investi-
gator. This study was conducted in accordance with the 
amended Declaration of Helsinki. All local ethics commit-
tees of participating institutions were approved, and all 
subjects provided written informed consent.
Study Subjects
Subjects aged between 40 and 75 years with a diagnosis of 
moderate to severe symptomatic COPD (post-bronchodilator 
ratio of FEV1/FVC <0.70 and FEV1 30–60% of predicted), 
a modified Medical Research Council (mMRC) dyspnea 
grade ≥2 or COPD assessment test (CAT) score ≥10 were 
enrolled (GOLD B or D subjects), as previously described.27 
Major exclusion criteria were more than two respiratory- 
related hospitalizations within the past year, gastroparesis 
cardinal symptom index (GCSI) ≥18,28 and previous lung 
or chest procedure.27
All patient inhaler usage was documented at screen-
ing. A wash-out period for long-acting muscarinic antago-
nists (LAMA) for 7 days, long-acting beta-agonist 
(LABA) and short-acting muscarinic antagonist 
(SAMA) and short-acting beta-agonist (SABA) for 12 
hours were employed. Following washout, all subjects 
were placed on inhaled tiotropium 18μg per day, and 
could continue with the prior inhalers, including inhaled 
corticosteroids, at the discretion of their physician, for 
7–21 days prior to their Run-In procedure testing. On 
the day of study pre-procedure testing, subjects were 
evaluated prior to the daily tiotropium dose (24 hours) 
and post-tiotropium administration for both trough and 
peak measures, ie, Run-In Trough and Run-In Peak. All 
subjects were encouraged to continue LAMA and other 
maintenance medications throughout the study follow-up 
period.
Study Procedures
As previously described, subjects underwent spirometry, 
body plethysmography, and health-related quality of life 
questionnaire (eg, COPD-specific St. George’s Respiratory 
Questionnaire (SGRQ-C)) at baseline and pre-defined fol-
low-up appointments at 6.5 months, 12.5 months and 
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yearly out to 3 years.27 Briefly, subjects allocated to the 
TLD arm received Nuvaira lung denervation therapy 
(Nuvaira, Inc.), which deploys radiofrequency (RF) energy 
to ablate the bronchial branches of the vagus nerve while 
protecting the bronchial mucosa utilizing a dual-cooled 
catheter. Subjects allocated to the sham arm underwent 
a mock procedure to maintain blinding. Following the 
12.5-month follow-up visit, all participants in the sham 
group had the opportunity to undergo TLD therapy, ie, 
cross-over. Cross-over could occur at any timepoint during 
follow-up after the 12.5-month follow-up visit. COPD 
exacerbations severity for the AIRFLOW-2 was defined 
previously.27 Briefly, moderate or severe COPD exacerba-
tions were defined as COPD exacerbations requiring treat-
ment with systemic steroids and/or antibiotics, with or 
without hospitalization. All adverse events were reported 
and tracked throughout the study.
Statistical Methods
Statistical hypothesis tests are based on t-tests for contin-
uous data that are normally distributed. Non-parametric 
tests were performed when there was evidence of non- 
normality. Fisher’s exact test was used to compare catego-
rical data. Annualized rate comparisons were performed 
using negative binomial regression analysis. Comparisons 
between groups of time to event data, such as time to first 
COPD exacerbation, were accomplished using a standard 
Log rank statistic. Analysis was performed using Minitab 
(Version 18.1, 2017) and SAS (Version 9.4, 2020). P<0.05 
was considered statistically significant.
Results
Patient Disposition
As described previously,27 the study inclusion was conducted 
between July 2016 and May 2017. One hundred and ninety- 
four subjects were screened and 82 subjects were rando-
mized. At enrollment, 95% of subjects were either managed 
via dual or triple therapy and complied with the tiotropium 
protocol requirement.27 Demographics of the control and 
TLD groups at baseline and 2 years are provided in Table 
1. In total, the TLD arm had a retention of 88% at 2 years 
(n=36), whereas the control arm group was reduced (n=14) 
as 49% of control subjects (n=20) underwent an optional 
cross-over procedure and 5 subjects voluntarily exited due 
to crossover ineligibility or other reasons (Figure 1). Control 
patients who underwent a cross-over procedure were cen-
sored from the adverse event annualized rate and time-to- 
event analysis at the time of cross-over and are not included 
in other variable analysis as they did not complete a full 
2-year follow-up time period.
Long-Term Safety Assessment: All 
Adverse Events
Differences in the percent of patients with severe AEs were 
non-significant in year 2 (p=0.72) between the Control and 
TLD arms with a lower, but non-significant difference in 
respiratory SAEs favoring the TLD group (p=0.19). In the 
treatment arm, a single severe gastrointestinal AE was 
reported 507 days post-procedure in the treatment arm with 
an inconclusive relationship to the TLD procedure (Figure 2). 
In the TLD arm, respiratory (n=4) and gastrointestinal (n=1) 
severe AEs were reported, as well as three patients with severe 
AE classifications which were unrelated to TLD: musculos-
keletal and connective tissue disorders (n=1), reproductive 
system (n=1), and skin and subcutaneous tissue disorder 
(n=1; Figure 2). Additionally, the control arm had respiratory 
(n=4), cardiac disorder (n=1) and psychiatric severe AEs 
(n=1; Figure 2). In the second year of follow-up, 11.1% of 
TLD subjects (n=4) experienced a respiratory-related hospita-
lization, compared to 28.6% of control subjects (n=4). These 
events resolved. Hospitalizations in the year prior to randomi-
zation were 24% for each group.27
Long-Term Safety Assessment: COPD 
Adverse Events
The risk of a severe COPD exacerbation requiring hospi-
talization was significantly lower in the TLD group than 
the control group at 2 years post-randomization, as 
assessed in a time-to-first event analysis (Figure 3, 
p=0.04, HR=0.38; 95% CI 0.15–0.99). There was no sta-
tistical difference in risk of first moderate or severe COPD 
exacerbation from baseline to 2 years (Figure 4, p=0.18, 
HR=0.71, 95% CI 0.42–1.18).
AEs were also evaluated in terms of annualized rate. 
There was not a statistically significant difference between 
groups for the annualized rate of COPD moderate and severe 
exacerbations (Control=0.81 vs TLD=0.64; p=0.54, Table 2) 
or for the severe COPD AEs (Control=0.15 vs TLD=0.11; 
p=0.71, Table 2) annualized rate at 2 years.
Lung Function and Quality of Life 
Assessment
To assess lung function, pulmonary function test results 
performed at the 2-year follow-up visit were compared to 
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initial Run-In visit test results. Approximately 94% of TLD 
(n=34) and 79% of control (n=11) subjects completed the in- 
person follow-up visit; remote visits were attempted for 
patients unable to complete the in-person follow-up visit to 
collect disease severity and quality of life assessment. All 
results were analyzed prior to daily drug administration, ie, 
trough. Lung function remained stable out to 2 years in the 
treatment arm. Specifically, FEV1 remained stable (Table 3; 
p=0.44),29 as well as FVC (p=0.51), TLC (p=0.66), and RV 
(p=0.84). The control group had increased variability at 2 
years, with trends of improvements in lung function noted for 
FVC, RV, and TLC, likely due to the adjusted population 
demographic at the 2-year visit due to cross-over design. 
Despite the trends, no changes were statistically significant 
(Table 3). Additional lung function measurements are 
included in Table 3. Further, Quality of Life as measured 
by SGRQ-C assessment remained stable out to 2 years for the 
TLD (p=0.93) and control groups (p=0.78) compared to Run- 
In visit results. No differences in SGRQ-C were found 
between groups (p=0.69; Table 3).
Discussion
The current study was the open-label follow-up of 
a randomized, double-blinded, full sham bronchoscopy 
controlled study of targeted lung denervation in subjects 
with symptomatic COPD, with primary and secondary 
endpoints at 12.5 months previously reported.27 Here we 
presented long-term safety and durability of TLD’s 
impact on severe COPD exacerbations on top of main-
tenance inhaler therapy in a high retention 2-year fol-
low-up study. TLD was associated with a lower 
percentage of patients experiencing a severe COPD 
exacerbation over the second year of follow up, com-
pared to control subjects who underwent a sham proce-
dure, and a significant reduction in the risk of severe 
COPD exacerbations over the two years of follow up in 
a time to event analysis.
Safety
The safety profile of the TLD system and procedure was 
confirmed out to 2 years. Respiratory and gastrointestinal 
adverse events were decreased during the second year of 
follow-up, with only one gastrointestinal SAE reported 
507 days post-procedure. This is a meaningful drop of 
gastrointestinal SAEs in comparison to the 1st year of 
follow up and suggests that severe gastrointestinal events 
related to the procedure present during the periprocedural 
period (within 1 month) and are transient in nature.27 
Table 1 Characteristics of Subjects at Baseline27 and 2 Years
Population 
Characteristic










Age – yr 63.68 ± 7.0 63.71 ± 6.7 62.6±8.1 63.3±6.8 0.76
Male sex – no. (%) 19 (46.3) 22 (53.7) 7 (50.0) 19 (52.8) 1.0
BMI 25.66 ± 4.2 25.44 ± 3.8 25.7±5.6 25.6±3.9 0.94
Pack years – no. 48.63 ± 30.7 43.49 ± 22.6 55.9±32.3 43.8±24.0 0.15
Emphysema score – %* 25.34 ± 10.7 27.92 ± 12.9 27.5±10.6 29.7±12.9 0.57
Pulmonary Function, COPD Severity and Quality of Life (n)
Total SGRQ-C score ‡; (n) 51.72 ± 15.5 (41) 54.88 ± 17.7 (41) 50.74±16.78; (12) 52.90±16.03; (34) 0.69
CAT; (n) 18.9 ± 6.6 (41) 17.9 ± 6.7 (41) 18.72±8.15 (11) 19.12±7.50 (34) 0.88
mMRC; (n) 2.1 ± 0.6 (41) 2.3 ± 0.8 (41) 1.92±0.90 (12) 1.89±0.96 (35) 0.93
FEV1 (L); (n) 1.14 ± 0.32 (41) 1.18 ± 0.39 (41) 1.18±0.0.40; (11) 1.09±0.40; (30) 0.53
FEV1% Predicted; (n) 41.4 ± 7.2 (41) 41.9 ± 7.6 (41) 38.32 ± 8.34; (11) 39.57 ± 10.43; (30) 0.72
FVC (L); (n) 3.07 ± 1.05 (41) 3.11 ± 0.88 (41) 3.09 ± 0.77; (11) 2.97 ± 0.81; (30) 0.67
FVC % Predicted; (n) 89.4 ± 18.9 (41) 90.8 ± 16.2 (41) 81.83 ± 13.94; (11) 87.42 ± 18.24; (30) 0.36
Notes: *Emphysema score presented as % of voxels with attenuation below −950 Hounsfield Units and were calculated at washout. ‡Scores on the St. George’s Respiratory 
Questionnaire for COPD (SGRQ-C) range from 0 to 100, with a lower score indicating better health status. Population characteristics reported were calculated at the initial 
screening visit. Pulmonary function, COPD severity and quality of life assessments were made at screening visit on standard drug therapy at baseline and at Tio peak for 
2-year follow-up. Data are presented as means ± SD. Sample size (n) denoted for pulmonary function, COPD severity and quality of life metrics. There were no significant 
differences between groups. 
Abbreviations: BMI, body mass index; SGRQ-C, Saint George’s Respiratory Questionnaire for COPD; CAT, COPD assessment questionnaire; mMRC, modified medical 
research council dyspnea score; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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Additionally, a reduction of severe AECOPD out to two 
years post treatment with TLD is reported (Figure 3). 
These data suggest a sustained impact of the TLD therapy 
on COPD exacerbation out to two years post procedure in 
the treatment arm. A regression to the mean in the treat-
ment arm represented by a converging of the time-to-event 
curves or increase in rate of COPD exacerbations in 
the second year would have been expected if the treatment 
effect was transient. There was no regression to the mean 
in the observed data set which demonstrated continued 
separation of the treatment and control arms in 
the second year of follow-up. This data is additive to the 
previously reported reduction in severe AECOPD follow-
ing 1-year post-TLD therapy.27
Clinical Impact
COPD exacerbations are known to have an impact on 
overall population health and healthcare costs, despite 
optimal pharmaceutical therapy.1,5,30,31 Further, COPD 
exacerbations are associated with an increased mortality 
rate,2 with one severe COPD event associated with a 14- 
times increase in risk of death and moderate COPD 
Figure 1 AIRFLOW-2 Study Subject Flow at major study timepoints with sample size numbers denoted in parentheses. Subjects were unblinded at the 1-year follow-up 
appointment and those in the sham-control group were offered the opportunity to cross-over and undergo the TLD procedure. Cross-over subjects (n=20) underwent the 
TLD procedure between the 1st and 2nd year follow-up visits. All other sham-control patients completed the 2-year follow-up visit, creating the control group (n=14). 
*Three patients unable to participate in the in-person follow-up visit for the control group (n=11 for pulmonary function tests).
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exacerbations associated with varying increased risk of 
death depending on frequency.6 In recent pharmacologic 
trials, while subjects were on dual or triple inhaler therapy, 
50–65% of GOLD D subjects had 1 or more moderate or 
severe exacerbations in one year of follow-up, represent-
ing an unmet clinical need.8,32,33
Figure 2 Percent (%) of patients experiencing a serious adverse event during the second year post-randomization for control (n=14; black bars) and TLD (n=36; diagonal 
stripe bars).
Figure 3 Time to first event analysis for severe chronic obstructive pulmonary disease (COPD) exacerbation. Cumulative incidence curve for the % of subjects that have 
had at least one severe COPD exacerbation over the course of follow-up (TLD = solid line, control = dashed line). Light gray vertical line indicates the start of the time 
period (417 days) when eligible patients could cross-over. Number of patients at risk includes patients still enrolled in the study who have not been censored out due to (1) 
a COPD event, (2) study exit, or (3) cross-over procedure.
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A reduction in COPD exacerbations following TLD 
therefore may have the potential to decrease both healthcare 
costs and mortality risk. While marked improvements in 
lung function were not observed, TLD was performed in 
COPD subjects who experienced a high exacerbation rate 
despite optimal medical therapy. It is known that pharma-
cologic therapy attenuates daily symptoms and improves 
lung function, whereas TLD prevents exacerbations 
through a blunted vagal response to stimuli. Therefore, 
early data suggest optimal clinical outcomes may result 
through a combination of pharmacologic therapy and TLD.
Lung Function and Quality of Life
The temporal progression of lung function for COPD sub-
jects is highly variable;34 however, a standard decrease of 
approximately 47–59 mL per year in FEV1 is anticipated 
for GOLD 2 and 3 patients, with a standard decrease of 
~35 mL anticipated for GOLD 4 patients.35 Despite this 
anticipated decline in lung function in similar populations, 
FEV1 and FVC values remained stable out to 2 years.29 
Similarly, SGRQ-C remained stable out to 2 years. Over 
two years of follow-up in this patient population it would 
be expected that the SGRQ-C measures would have dete-
riorated by ~2 pts per year.36 A larger clinical study is 
needed to determine the impact of TLD on patient quality 
of life.37 The variability in lung function in the control 
group was not surprising due to the small sample size 
(n=11) able to complete the in-person 2nd year follow-up 
visit due to cross-over.
Limitations
In addition to the strengths and weaknesses previously 
documented,27 the small sample size was an enhanced 
limitation in this report. While an improvement in the 
time-to-first event is seen in the TLD group, this result 
was found in a relatively small study size. This sample 
size was further decreased after approximately 50% of 
control subjects crossed over before the 2-year follow-up 
visit, which likely resulted in a healthier group, ie, subjects 
who had a higher symptomatic disease characteristic were 
Figure 4 Time to first event analysis for Moderate or Severe chronic obstructive pulmonary disease (COPD) exacerbations. Cumulative incidence curve for the % of 
subjects that have had at least one moderate or severe COPD exacerbation over the course of follow-up (TLD = solid line, control = dashed line). Light gray vertical line 
indicates the start of the time period (417 days) when eligible patients could cross-over. Number of patients at risk includes patients still enrolled in the study who have not 
been censored out due to (1) a COPD event, (2) study exit, or (3) cross-over procedure.
International Journal of Chronic Obstructive Pulmonary Disease 2020:15                                          submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2813


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
more likely to undergo TLD, which is a well-known 
challenge of cross-over design.38
Conclusion
Here we report that the clinical impact of TLD is durable, 
as it is found to reduce the risk of serious COPD adverse 
events over 2 years with stabilized lung function. The 
reduction of severe COPD exacerbations has the potential 
to improve long-term clinical outcomes and reduce health-
care costs. Further study in a large population is warranted 
to confirm the healthcare impact of TLD.
Abbreviations
AE, adverse events; BMI, body mass index; CAT, COPD 
assessment test; COPD, chronic obstructive pulmonary 
disease; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; ICS, inhaled corticosteroid; 
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Global Obstructive Lung Disease; LABA, long acting 
beta agonist; LAMA, long acting muscarinic antagonist; 
MCID, minimal clinically important difference; mMRC, 
modified Medical Research Council; RF, radiofrequency; 
RV, residual volume; SABA, short acting beta agonist; 
SAMA, short acting muscarinic antagonist; SGRQ-C, 
St. George’s Respiratory Questionnaire; TLC, total lung 
capacity; TLD, targeted lung denervation.
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Table 3 Pulmonary Function and SGRQ-C Assessments
Comparisons Made from Run-In Tiotropium Trough
Outcome Measures Mean ± SD (n) 2 Year
Control TLD
FEV1 Absolute Change (L) −0.05 ± 0.21 (11) −0.02 ± 0.14 (30)
FVC Absolute Change (L) 0.11 ±0.54 (11) −0.14 ± 0.29 (30)
TLC Absolute Change (L) −0.24 ± 0.52 (11) 0.04±0.44 (30)
RV Absolute Change (L) −0.31 ± 0.45 (11) 0.21 ± 0.53 (30)
SGRQ-C Absolute Change −0.03±15.02 (12) 1.81±12.66 (34)
Notes: All p values are non-significant. Values are differences between 1 Year and 2 Year run-in tiotropium trough. Pulmonary function measures were evaluated when 
subjects were in pharmaceutical trough for those patients able to participate in an in-person follow-up visit. Mean ± SD (N). There were no significant differences between 
groups. 
Abbreviations: TLD, targeted lung denervation; SGRQ-C, St. George’s Respiratory Questionnaire for COPD.
Table 2 Annualized Rate of AECOPDs
Year 1 Year 2
Control TLD Control TLD
Moderate and Severe AECOPDs Annual Rate 1.16 1.09 0.81 0.64
No. AECOPDs 54 50 20 23
Follow-up Years 46.6 45.7 24.8 35.8
P-value p=0.90 p=0.54
Severe AECOPDs Annual Rate 0.39 0.24 0.16 0.11
No. AECOPDs 18 11 4 4
Follow-up Years 46.6 45.7 24.8 35.8
P-value p=0.43 p=0.71
Notes: Analysis includes all AECOPDs occurring within the study time window of year 1 (0–417 Days) or year 2 (418–765 Days). Subjects were censored at the time of 
study exit or crossover procedure when applicable.
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not plan to share individual deidentified participant data. The 
study protocol has been made available with the publication 
of the 1-year data (Slebos et al. AJRCCM 2019).
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